| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H18ClIN6O4 |
| Molecular Weight | 544.731 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=C(Cl)N=C3NCC4=CC=CC(I)=C4
InChI
InChIKey=IPSYPUKKXMNCNQ-PFHKOEEOSA-N
InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
| Molecular Formula | C18H18ClIN6O4 |
| Molecular Weight | 544.731 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CF102 known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5’- N-methyl-uronamide), is a highly specific and selective agonist at the A3 adenosine receptor. Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of CF102. A global Phase II study treating patients with CF102 as a second line therapy will start enroling patients shortly.
CNS Activity
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
The primary objectives of a phase I/II, open-label, dose-escalation study were to examine the safety and pharmacokinetic behavior of CF102 given orally (1, 5, and 25 mg BID) in 28-day cycles.
Route of Administration:
Oral
